Bank Of New York Mellon Corp Cullinan Oncology, Inc. Transaction History

Bank Of New York Mellon Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$10.2 - $11.91 $981,647 - $1.15 Million	96,240 New	96,240 $985 Million
Q4 2022 Feb 14, 2023	BUY	$9.72 - $13.62 $1.06 Million - $1.48 Million	109,011 New	109,011 $1.15 Million
Q3 2022 Nov 14, 2022	BUY	$11.82 - $15.42 $160,444 - $209,311	13,574 Added 14.71%	105,878 $1.36 Million
Q2 2022 Aug 15, 2022	SELL	$7.31 - $13.55 $6,432 - $11,924	-880 Reduced 0.94%	92,304 $1.18 Million
Q1 2022 May 11, 2022	SELL	$10.47 - $16.75 $23,442 - $37,503	-2,239 Reduced 2.35%	93,184 $975,000
Q4 2021 Feb 11, 2022	BUY	$15.36 - $25.0 $234,378 - $381,475	15,259 Added 19.03%	95,423 $1.47 Million
Q3 2021 Nov 12, 2021	BUY	$22.56 - $29.68 $914,514 - $1.2 Million	40,537 Added 102.3%	80,164 $1.81 Million
Q2 2021 Aug 11, 2021	BUY	$24.96 - $41.25 $119,857 - $198,082	4,802 Added 13.79%	39,627 $1.02 Million
Q1 2021 May 13, 2021	BUY	$28.0 - $53.42 $975,100 - $1.86 Million	34,825 New	34,825 $1.45 Million

146

67.6M

612K

118K

Ticker CGEM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,612,200
Market Cap $499M
Description
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.